NewLimit

NewLimit aims to increase how long people can live a healthy life by genetically programming their cells. The company is developing treatments that can restore youthful characteristics to aged cells, specifically focusing on reprogramming liver cells. They are employing an AI model to accelerate the development and testing of new anti-aging medicines.

Funding Round: Series B

Funding Amount: $130M

Date: 06-May-2025

Investors: Kleiner Perkins, Nat Friedman, Daniel Gross, Khosla Ventures, Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison, and others

Markets: Biotech, Healthtech, Drug Discovery

HQ: South San Francisco, California, United States

Founded: 2021

Website: https://www.newlimit.com/

LinkedIn: https://www.linkedin.com/company/newlimit

Twitter: https://twitter.com/newlimit

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/newlimit/company_financials

Pitchbook: https://pitchbook.com/profiles/company/489108-07